Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance
title

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits

 

escrs app advert yo advert

Posters

Search Title by author or title

Evaluations of corneas and anterior segments in eyes with coeliac disease in paediatric population

Poster Details

First Author: A. Karatepe Hashas TURKEY

Co Author(s):    O. Altunel   E. Sevinc   N. Duru   B. Alabay   Y. Altuner Torun        

Abstract Details

Purpose:

To determine the differences in the corneas and anterior segments of eyes in children with Celiac disease (CD).

Setting:

Prospective case control study

Methods:

Thirty- one children with classic CD, aged 18 months-18 years, were included in the presented study. Thirtyfour age and sex matched healthy children were included as the control group. In addition to a complete ophthalmologic examination, all patients were scanned by Pentacam Scheimpflug camera in the dark, and dry eye tests -Schirmer and break-up time (BUT) tests were performed. Data entered using SPSS software were then evaluated by paired t-test; p < 0.05 value was considered statistically significant.

Results:

The eyes in children with CD were not found different in central corneal thickness or endothelial cell count; however they were statistically found to have decreased anterior chamber depth ( 3.5 ± 0.2, 3.7 ± 0.2; p<0.001), and decreased anterior chamber volume ( 170.8 ± 25.5, 190.7 ± 27.4; p<0.001), lower Shirmer ( 17.9 ± 9.1, 21.6 ± 4.1; p=0.038), and lower BUT ( 10.8 ± 3.8, 12.1 ± 1.7; p=0.046) measurements. There is no correlation between anti-endomysium antibodies level or stage of disease and anterior chamber parameters and dry eye tests.

Conclusions:

We have determined that a number of factors such as anterior chamber parameters and dry eye tests, are different from those of normal eyes. These differences should be taken into account in the follow-up and treatment of eyes in children with CD.

Financial Disclosure:

NONE

Back to Poster listing